Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

college * combination 35

12th World AIDS Conference

SKeyword Abstract
d threat of AIDS among students: Motivational and person 24155
and value orientation of women: An experience in sustaini 24366
and alcohol use among students/Sexual behaviors and al 60047
ons at historically black and university campuses 1995-96 60511
nts of high schools and colleges /Survey of information sources o 13516
H in secondary training /Peer education on ARH in secon 13554
with men/When worlds collide: Sex, needles, and HIV infection a 23104
o border/When worlds - North meets South: AIDS on the 34369
ainst STD/AIDS among Colombian women/Social and sexual beh 14292
IDS patients treated at Colombo, Sri Lanka/Prevalence of fungal 31215
IV-1 tropism for human colonic cells and astrocytes/The common 11118
a German study group/ Colonisation and dissemination of HIV-rel 60170
etween oropharyngeal colonization with Candida and plasma HI 22214
tion and STDs/Vaginal with lactobacillus species, ab 33148
Staphylococcus aureus related to the clinical parame 60575
gent use/Utilisation of colony stimulating factors (CSF) in an HIV 42436
linical trials laboratory/ Color method validation for HIV+ CD4 anal 42205
nity/Serving people of color in the US: Federal efforts to ensure t 32432
ategies for gay youth of in the "house" community/HIV/AIDS 43338
portunistic infections: A Doppler echocardiographic study/P 60995
moral immune factors in colostrum of HIV infected and non-infecte 31163
WIHS)/Adherence with colposcopy among women in the Women' 22320
CL) in HIV+ women in a clinic in Guadalajara, Mexico 60396
laxis program in British Columbia, Canada/A critical assessment 60162
ated behaviour among Columbian female, male, and transsexual 60258
e uniformly during triple combination-therapy of HIV-1 infection/ 41164
alog during pregnancy/ Combination therapy with nevirapine, zid 463*/12152
oad >5000 copies/ml/ abacavir (1592, ABC)/ampr 286*/12204
r in children with HIV-1/ antiretroviral therapy includi 12259
n HIV-infected children/ therapy with saquinavir soft 12260
dvanced HIV infection/ therapy with a protease inhi 12262
pediatric HIV infection/ antiretroviral therapy with rit 12296
hibitor (+)-calanolide A/ anti-HIV interactions and re 12366
d by a single physician/ therapy with protease-inhibit 22354
mmune reconstitution/ therapy with nelfinavir, stav 22362
) experienced patients/ therapy with nelfinavir/saqui 22391
e with enzyme activity/ of the multidrug resistance 32300
h care workers (HCW)/ post-exposure prophylaxis ( 33175
ty in the Indian context/ drug therapy: Inaccessibility 44177
stic infection treatment/ therapies including protease 44247
espite other therapies/ therapy with recombinant hu 60389,France, 1992-1997)/ of two nucleoside analogue 60411
d experienced patients/ therapy with nevirapine in tr 60701
ase inhibitor-containing combination therapy through a dissociate 341*/12101
mulation of saquinavir in with two nucleosides in treat 12145
nd virological effects of antiretroviral therapy: Primar 12193
d/or efavirenz (EFV) in with new nucleoside analogs 125*/12203
DLV resistance during therapy with zidovudine (ZD 12206
dy of ritonavir-nelfinavir therapy: An update/Phase II 12207
dy of protease inhibitor in Europe (SPICE): Saquina 290*/12222
iracept (nelfinavir) in with stavudine (d4T) and lam 12224
ne (ddl), and nelfinavir therapy in pretreated HIV-pa 12226
/nucleoside (NVP/nuc) therapy/Retained effectiven 12231
dults/Hydroxyurea in regimens for the treatment of 287*/12235
nient highly active triple for first line antiretroviral ther 12239
valuate the efficacy of antiviral therapy with ZDV 20 12240
oft gel capsule (SGC) in with d4T/DDC/MIKADO: Sa 12244
cted children receiving therapy/Mutation pattern of t 12257
vudine plus zalcitabine therapy versus NAIV childre 12263
dinavir containing triple regimen/Clinical trial compa 12265
le or indinavir as part of triple therapy (CHEESE stud 292*/12267
Salvage therapy with a including nelfinavir in patient 12285
s (q8H) versus q12H in with efavirenz (EFV)/Sixtee 12290
ients treated by a triple therapy with protease inhibit 12297
reatment with Viracept treatment as predictor of res 12300
ft gel capsule (SGC) in with AZT and 3TC in antiretr 12301
men + HIV-infected with nelfinavir, saquinavir, stavud 12305
mm3/lndinavir (IDV) in with zidovudine (ZDV) and la 12311
toxicity of antiretroviral treatment: Data on 4230 pati 12312
) SGC BID regimens in with 2 nucleosides or nelfina 12314
s of ritonavir/saquinavir salvage therapy/Efficacy an 12316
ildren/Effectiveness of with protease inhibitors in th 12320
vel protease inhibitor, in with zidovudine/3TC/Phase 12321

pon commencement of antiretroviral drug therapy/I 12323
treated with ritonavir in therapy for HIV infection at I 12333
ficacy and safety of the of ritonavir plus saquinavir, 12336
atients/Tolerability of therapy with protease inhibit 12349
Indinavir (Crixivan~) in with two nucleoside reverse t 12350
stration of didanosine in with stavudine/STADI: Sust 12351
592, ABC) alone and in therapy of HIV infection/Saf 12353

Keyword

Abstrac

efavirenz (DMP 266) in
V-1-infected cells/Drug
evirapine (NVP) based
ring monotherapy or in
g stavudine-didanosine
Patterns of nausea with
of life before and during
n a comparative trial of
eated with antiretroviral
prophylaxis in the era of
HIV infection/Access to
STIVATM, DMP 266) in
Sustiva"m DMP 266) in
nd tolerability of the
nd safety of triple drug
hibitors/Efficacy of the
in Italy: The role of new
portunistic disease with
le HIV RNA induced by
clinical practice/"Triple
(WIHS)/Penetrance of
nts/Same antiretroviral
y of nelfinavir (NFV) in
wing antiretroviral triple
Saquinavir (RTV/SQV)
d study of Rescriptor in
s in use of antiretroviral
ation with saquinavir in
iral effect of a four-drug
reated with nelfinavir in
ell counts/Antiretroviral
reatment of ritonavir in
tabine zidovudine triple
h AIDS after successful
with HIV/The impacts of
ctors and adherence to
eceiving highly active
sease progression and
patients receiving triple
ements accompanying
patients receiving triple
ns in patients under the
n using quadruple drug
atients failing tritherapy
atients treated with a
ts receiving a four-drug
eutic failure to d4T/3TC
n ZDV/3TC/amprenavir
related to adherence to
-reported adherence to
ected patients receiving
Compliance to multiple
of non adherence to HIV
reatment adherence to
/Patient compliance on
ily dosing antiretroviral
nscriptase inhibitors or
A experience: Applying
avir in pregnancy/Triple
hylaxis/Zidovudine and
ibody responses with a
he light of advances in
antiretroviral mono and
tic HIV-infection/Triple
non-toxic, inexpensive
ents/The effect of triple
IV replication in vitro in
ct of AZT versus d4T in
tion of apoptosis during
e to AZT and 3TC after
comparison/Uptake of
+ women/Predictors of
ase reports of potential
gical analysis of a triple
men/The impact of new

Scotland/The effect of
ra of antiretroviral triple
infected patients under
) in patients on antiviral
dofovir and ganciclovir

with indinavir (IDV) [DMP 26
studies on MKC-442 with RT
therapy within the INCAS tria
with ritonavir in patients with
therapy (QUINTET Trial)/Pe
antiretroviral therapy inducti
antiretroviral treatment in ant
antiretroviral therapy in a Th
regimens?/Is it safe to stop
anti-retroviral therapy/The r
antiretroviral therapy (CART
with open-label zidovudine (
with open-label zidovudine (
of efavirenz (EFV, sustivaM,
antiretroviral regimens for th
stavudine (d4T), didanosine
antiretroviral therapies/Incre
antiretroviral therapy/Declin
antiretroviral therapy/A coh
"therapy with nevirapine in a
antiretroviral therapy into the
proves highly or poorly effect
with efavirenz (EFV, SUSTI
/Reconstitution of lymph nod
in protease inhibitor (PI) naiv
with zidovudine and two dos
therapy are the most likely c
with ritonavir and double nuc
in plasma and lymph node c
with AZT and 3TC for greater
therapy in patients with low
with zidovudine (ZDV/AZT) a
/Experience with saquinavir
therapy/Living revisited: Th
therapies on the lives of peo
therapies: A pilot study/Psyc
therapy/Down regulation of
antiretroviral therapy upon H
therapy/Worsening of HIV-1
anti-retroviral therapy/Cogni
therapy/Discrepant immuno
therapy (CT)/Skin manifesta
therapy in treatment experie
/Prevalence of resistance-as
of ritonavir and saquinavir (A
therapy/Genotypic resistanc
/M184V mutation is not predi
therapy/Genotypic and phe
therapy in HIV-1 positive gay
antiretroviral medication (AR
anti-retroviral therapy/Evalu
therapy with antiprotease in
therapies/Predictors of non
antiretroviral therapy/Servic
HIV anti-retroviral therapies/
therapy/Nevirapine (NVP) +
therapy among HIV+ women
antiretroviral therapy in a US
therapy including nelfinavir i
antiretroviral post exposure
HIV-1 vaccine regimen/CTL
drug treatment/UK ASO pro
therapy/Response of HIV vir
therapy and change in perip
of didanosine plus hydroxyur
in HIV-1 experienced patient
with other anti-HIV agents/A
with 3TC and indinavir in the
therapy/Modification of apo
treatment with indinavir/Low
anti-retroviral therapy during
antiretroviral therapy use in
therapy using botanical subs
pilot study and traditional dru
HIV therapies on knowledge

therapy on long-term HIV dis
therapy/Modelling disease p
therapy containing a proteas
therapy with a HIV-1 RNA <
therapy for treatment of cyto

ct
12359
12362
12368
12378
12397
12402
12444
14357
22180
22182
22333
22334
22340
22343
22348
22357
22367
22374
22377
22378
22380
22382
22386
22389
22390
22393
22394
22395
22397
22400
22408
22409
22410
24259
640*/24260
24282
110*/31165
32112
32154
32255
342*/32259
32271
32295
32301
32302
32304
32310
32312
32331
32338
32351
32359
32375
32383
32384
32393
32399
32405
32419
33182
33221
34315
41141
339*/41178
41180
41189
41195
42169
42184
42197
42289
42311
42388

42395
43260
43471
43474
60118
60181
60195